CUSIP 18270P109 · who reports it, how much, and how much it matters to them
12 of the 720 hedge fund managers we track reported shares of Clarus Corp (Nasdaq: CLAR) on Form 13F for 30 June 2026. Between them they reported USD 8.2m. The largest position belongs to Marshall Wace LLP, at USD 2.2m. The manager with the most riding on it is Lepercq de Neuflize Asset Management, where it is 0.1% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Marshall Wace LLP84 funds on PPLI.com | USD 2.2m | 0.0% |
| 2 | D. E. Shaw & Co.15 funds on PPLI.com | USD 1.2m | 0.0% |
| 3 | Gamco Asset Management1 fund on PPLI.com | USD 1.1m | 0.0% |
| 4 | Castleknight Management3 funds on PPLI.com | USD 995,000 | 0.0% |
| 5 | Two Sigma Investments35 funds on PPLI.com | USD 701,000 | 0.0% |
| 6 | Citadel Advisors32 funds on PPLI.com | USD 680,000 | 0.0% |
| 7 | Millennium Management6 funds on PPLI.com | USD 430,000 | 0.0% |
| 8 | Squarepoint Ops7 funds on PPLI.com | USD 401,000 | 0.0% |
| 9 | Lepercq de Neuflize Asset Management2 funds on PPLI.com | USD 175,000 | 0.1% |
| 10 | Prelude Capital Management9 funds on PPLI.com | USD 158,000 | 0.0% |
| 11 | Jain Global1 fund on PPLI.com | USD 90,695 | 0.0% |
| 12 | POINT72 Asset Management17 funds on PPLI.com | USD 86,779 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Lepercq de Neuflize Asset Management | USD 175,000 | 0.1% |
| 2 | Castleknight Management | USD 995,000 | 0.0% |
| 3 | Prelude Capital Management | USD 158,000 | 0.0% |
| 4 | Gamco Asset Management | USD 1.1m | 0.0% |
| 5 | Marshall Wace LLP | USD 2.2m | 0.0% |
| 6 | D. E. Shaw & Co. | USD 1.2m | 0.0% |
| 7 | Two Sigma Investments | USD 701,000 | 0.0% |
| 8 | Citadel Advisors | USD 680,000 | 0.0% |
| 9 | Millennium Management | USD 430,000 | 0.0% |
| 10 | Squarepoint Ops | USD 401,000 | 0.0% |
Clarus Corp trades under the symbol CLAR on the Nasdaq. Its CUSIP, the code used on Form 13F, is 18270P109.
12 of the 720 hedge fund managers PPLI.com tracks reported Clarus Corp shares on Form 13F for 30 June 2026. The largest reported positions were held by Marshall Wace LLP (USD 2.2m), D. E. Shaw & Co. (USD 1.2m), Gamco Asset Management (USD 1.1m), Castleknight Management (USD 995,000) and Two Sigma Investments (USD 701,000).
12 managers in our coverage reported it, and between them they run 212 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Lepercq de Neuflize Asset Management, where the position was 0.1% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Clarus Corp or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.